Description

Niacin (Nicotinic Acid)

Immediate-Release | Pure Crystalline Powder

Nicotinic acid is the biologically conserved, direct precursor to NAD⁺ in human metabolism. This product provides nicotinic acid in its unmodified, immediate-release crystalline form, at 100% purity meeting the most stringent USP standard for quality control and purity.

The material is sourced and handled with an emphasis on chemical purity and traceability, consistent with laboratory-grade standards. Certificates Of Analysis (COA) and Origin (COO) reflect a commitment to known inputs, not blended or reformulated consumer substitutes.

This is not a time-release, buffered, or “flush-free” derivative. It is 100% nicotinic acid, offered as a powder to allow precise, titratable dosing.

---

Why Purity and Form Matter

Nicotinic acid’s role in NAD⁺ synthesis depends on its direct entry into the Preiss–Handler pathway. Modified, esterified, buffered, or delayed-release forms may alter absorption kinetics, receptor engagement, and metabolic routing, introducing unnecessary uncertainty when working with a limiting substrate.

Immediate-release crystalline nicotinic acid allows:

Predictable absorption

Transparent dose–response

Clear physiologic feedback

Direct Preiss–Handler pathway entry

For individuals rebuilding from deficiency, long-term depletion, or disrupted tryptophan–NAD⁺ metabolism, simplicity and purity are advantages, not inconveniences.

---

Relationship to D-Tryptophan and NIASCEND

Nicotinic acid and D-tryptophan are metabolically linked through NAD⁺ synthesis, indole metabolism, glutamine–glutamate turnover, and protein–energy balance.

In the NIASCEND model, nicotinic acid functions as the larger NAD⁺ payload, while D-tryptophan functions as the smaller indole-side signal precursor.

The current coupled ratio is:

139.3 parts nicotinic acid : 1 part D-tryptophan

This ratio is designed around the proposed conversion logic that D-tryptophan can move through D-amino acid oxidase toward indole-3-pyruvic acid (I3PA), while nicotinic acid moves through the Preiss–Handler pathway toward NAD⁺.

At the final NAD synthetase step, glutamine utilization can support glutamate availability. That glutamate may then provide the amino-donor pressure needed for I3PA to move back toward L-tryptophan through aminotransferase chemistry.

In this model, nicotinic acid does not simply act as vitamin B₃ alone. It helps create the metabolic context for D-tryptophan-derived I3PA to be redirected toward usable L-tryptophan rather than being lost into oxidative degradation.

In this context, nicotinic acid can function as:

An anchor substrate during early repletion

A direct Preiss–Handler NAD⁺ precursor

A tool for controlled titration of vitamin B₃

The payload side of the D-tryptophan / I3PA / L-tryptophan restoration model

A preparatory step before transitioning to NIASCEND, which is designed to provide nicotinic acid and D-tryptophan in a defined, coupled ratio for long-term use

Once tolerance is established and the user is ready for a more integrated formulation, many individuals may prefer to consolidate into NIASCEND as a single paired product.

This product exists to support that staged, intentional progression, not to replace NIASCEND.

---

The Payload Role of Nicotinic Acid

Nicotinic acid is the payload side of the Shield & Deposit model.

The proposed sequence is:

Nicotinic acid → NaMN → NAAD → NAD⁺

At the same time:

D-tryptophan → indole-3-pyruvic acid → L-tryptophan

The purpose of the nicotinic acid payload is to support NAD⁺ synthesis directly so the body does not need to rely as heavily on degrading L-tryptophan through the kynurenine pathway.

In simple terms:

Nicotinic acid reduces the pull.
D-tryptophan supplies the signal.
I3PA preserves the indole ring.
Glutamate supports the bridge.
L-tryptophan becomes the deposit.

This is the core logic behind the paired NIASCEND ratio.

---

Composition

Active ingredient: Nicotinic Acid (Niacin)

Form: Free acid, crystalline powder

Release profile: Immediate-release

Other ingredients: None

---

Sensory and Physiologic Notes

Transient warmth, redness, tingling, or flushing may occur, particularly during initial use. This is a known, temporary response associated with immediate-release nicotinic acid’s active physiologic signaling.

In the NIASCEND model, this response is not treated as a defect of the product. It is understood as a visible and sensory marker of active nicotinic acid engagement.

Individual responses vary based on dose, timing, food intake, hydration, repeated exposure, and whether nicotinic acid is taken alone or paired with D-tryptophan.

The goal is not to chase intensity. The goal is controlled, disciplined use of the nicotinic acid payload.

---

Summary

Nicotinic acid is the immediate-release NAD⁺ payload side of the NIASCEND model.

It enters the Preiss–Handler pathway, supports NAD⁺ synthesis, and provides the metabolic context in which D-tryptophan-derived indole-3-pyruvic acid may be redirected toward usable L-tryptophan.

The defined coupled ratio is:

139.3 parts nicotinic acid : 1 part D-tryptophan

This individual nicotinic acid product exists for users who want access to the pure payload component for staged, intentional, and controlled use within the broader NIASCEND model.